VZV gE Antibody (9C8): sc-56995

VZV gE Antibody (9C8) is a mouse monoclonal IgG1 kappa light chain antibody that detects VZV gE protein of Varicella Zoster Virus origin by western blotting (WB) and immunofluorescence (IF). Anti-VZV gE antibody (9C8) is available as a non-conjugated isotype antibody. VZV gE protein plays a crucial role in the virus′s lifecycle, particularly in the process of viral entry and egress from host cells. VZV gE serves as a major component of the virion envelope and is essential for the formation of the glycoprotein E and glycoprotein I complex, which is vital for viral infection of new cells. The interaction between gE and gI not only facilitates virus envelopment within the trans-Golgi network but also aids in efficient membrane fusion necessary for viral replication. Understanding VZV gE function is important for developing therapeutic strategies against Varicella Zoster Virus, as VZV gE contributes to the pathogenesis of both chickenpox and shingles. Using VZV gE monoclonal antibody (9C8) in research can provide insights into VZV infection mechanisms and potential targeted interventions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

VZV gE Antibody (9C8) References:

1. Transcription factor Sp1 is involved in the regulation of varicella-zoster virus glycoprotein E.  |  Rahaus, M. and Wolff, MH. 2000. Virus Res. 69: 69-81. PMID: 10989187
2. Essential role played by the C-terminal domain of glycoprotein I in envelopment of varicella-zoster virus in the trans-Golgi network: interactions of glycoproteins with tegument.  |  Wang, ZH., et al. 2001. J Virol. 75: 323-40. PMID: 11119602
3. Varicella-Zoster virus infections of the nervous system: clinical and pathologic correlates.  |  Kleinschmidt-DeMasters, BK. and Gilden, DH. 2001. Arch Pathol Lab Med. 125: 770-80. PMID: 11371229
4. The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells.  |  Mo, C., et al. 2002. Virology. 304: 176-86. PMID: 12504560
5. Complex interaction between mutant HNRNPA1 and gE of varicella zoster virus in pathogenesis of multiple sclerosis.  |  Kattimani, Y. and Veerappa, AM. 2018. Autoimmunity. 51: 147-151. PMID: 29996671
6. Varicella-Zoster Virus infected human neurons are resistant to apoptosis.  |  Kennedy, PG., et al. 2020. J Neurovirol. 26: 330-337. PMID: 32125664
7. Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines.  |  Schmid, DS., et al. 2021. J Virol. 95: PMID: 33762414
8. Varicella zoster virus glycoprotein E facilitates PINK1/Parkin-mediated mitophagy to evade STING and MAVS-mediated antiviral innate immunity.  |  Oh, SJ., et al. 2024. Cell Death Dis. 15: 16. PMID: 38184594
9. Structures of the Varicella Zoster Virus Glycoprotein E and Epitope Mapping of Vaccine-Elicited Antibodies.  |  Harshbarger, WD., et al. 2024. Vaccines (Basel). 12: PMID: 39460278
10. Varicella-zoster virus glycoproteins E and I expressed in insect cells form a heterodimer that requires the N-terminal domain of glycoprotein I.  |  Kimura, H., et al. 1997. Virology. 233: 382-91. PMID: 9217061
11. Varicella-zoster virus glycoprotein I is essential for growth of virus in Vero cells.  |  Cohen, JI. and Nguyen, H. 1997. J Virol. 71: 6913-20. PMID: 9261418
12. Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking.  |  Mallory, S., et al. 1997. J Virol. 71: 8279-88. PMID: 9343180

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-VZV gE Antibody (9C8) has 12 citations in a variety of scientific publications.

Primary antibodies for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

VZV gE Antibody (9C8) Specifications

Alternate Product Name: VZV gE

Product Clone Name: 9C8

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: VZV gE

Epitope Species: Varicella Zoster virus

Product Reactivity/Detection: glycoprotein E

Species Reactivity/Detection: Varicella Zoster Virus

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IF

Vialing Information: Each vial contains 100 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 12 citations in various scientific publications

Available Conjugates/Forms for VZV gE Antibody (9C8): N/A